Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, USA; Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville School of Medicine, Louisville, KY, USA.
Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, USA; Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville School of Medicine, Louisville, KY, USA; UofL Health - Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, USA.
Antiviral Res. 2024 Jul;227:105901. doi: 10.1016/j.antiviral.2024.105901. Epub 2024 May 10.
Growing concerns regarding the emergence of highly transmissible viral diseases highlight the urgent need to expand the repertoire of antiviral therapeutics. For this reason, new strategies for neutralizing and inhibiting these viruses are necessary. A promising approach involves targeting the glycans present on the surfaces of enveloped viruses. Lectins, known for their ability to recognize specific carbohydrate molecules, offer the potential for glycan-targeted antiviral strategies. Indeed, numerous studies have reported the antiviral effects of various lectins of both endogenous and exogenous origins. However, many lectins in their natural forms, are not suitable for use as antiviral therapeutics due to toxicity, other unfavorable pharmacological effects, and/or unreliable manufacturing sources. Therefore, improvements are crucial for employing lectins as effective antiviral therapeutics. A novel approach to enhance lectins' suitability as pharmaceuticals could be the generation of recombinant lectin-Fc fusion proteins, termed "lectibodies." In this review, we discuss the scientific rationale behind lectin-based antiviral strategies and explore how lectibodies could facilitate the development of new antiviral therapeutics. We will also share our perspective on the potential of these molecules to transcend their potential use as antiviral agents.
人们对高传染性病毒疾病的出现越来越担忧，这凸显了扩大抗病毒治疗方法的迫切需求。出于这个原因，有必要针对这些病毒开发新的中和和抑制策略。一种很有前途的方法是针对包膜病毒表面存在的聚糖。凝集素以识别特定碳水化合物分子的能力而闻名，为糖基靶向抗病毒策略提供了可能。事实上，许多研究报告了各种内源性和外源性凝集素的抗病毒作用。然而，由于毒性、其他不利的药理作用和/或不可靠的制造来源，许多天然形式的凝集素不适合用作抗病毒疗法。因此，提高凝集素作为有效抗病毒疗法的适用性至关重要。一种增强凝集素作为药物适用性的新方法可能是生成重组凝集素-Fc 融合蛋白，称为“凝集素抗体”。在这篇综述中，我们讨论了基于凝集素的抗病毒策略的科学原理，并探讨了凝集素抗体如何促进新的抗病毒疗法的开发。我们还将分享我们对这些分子超越作为抗病毒剂的潜在用途的看法。
